Akorn Provides Preliminary Second Quarter 2019 Results
01 août 2019 07h00 HE
|
Akorn, Inc.
LAKE FOREST, Ill., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced its preliminary financial results for the second...
Akorn to Report Second Quarter 2019 Financial Results and Host Conference Call
11 juil. 2019 16h32 HE
|
Akorn, Inc.
LAKE FOREST, Ill., July 11, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that it plans to issue a press release before...
Akorn Announces Launch of Loteprednol Etabonate Ophthalmic Suspension, 0.5%
28 juin 2019 07h00 HE
|
Akorn, Inc.
LAKE FOREST, Ill., June 28, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that it has launched its first-to-market generic...
Akorn Receives FDA Warning Letter
25 juin 2019 07h35 HE
|
Akorn, Inc.
LAKE FOREST, Ill., June 25, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, announced that it received a warning letter from the U.S. Food...
Akorn to Present at the Jefferies 2019 Global Healthcare Conference
30 mai 2019 07h59 HE
|
Akorn, Inc.
LAKE FOREST, Ill., May 30, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that management will present at the Jefferies 2019...
Akorn Receives FDA Approval for Azelastine Hydrochloride Nasal Spray, 0.1%
20 mai 2019 16h05 HE
|
Akorn, Inc.
LAKE FOREST, Ill., May 20, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that it received a new Abbreviated New Drug...
Akorn to Present at the RBC Capital Markets Healthcare Conference
20 mai 2019 08h01 HE
|
Akorn, Inc.
LAKE FOREST, Ill., May 20, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that management will present at the 2019 RBC...
Akorn Provides Preliminary First Quarter 2019 Results and Full Year Guidance
07 mai 2019 07h05 HE
|
Akorn, Inc.
-Operational improvements drive sequential growth- -Full year outlook anticipates further sequential growth throughout the year- LAKE FOREST, Ill., May 07, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc....
Akorn Receives FDA Approval for Loteprednol Etabonate Ophthalmic Suspension, 0.5%
18 avr. 2019 17h00 HE
|
Akorn, Inc.
LAKE FOREST, Ill., April 18, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that it received a new Abbreviated New Drug...
Akorn Receives FDA Approval for Fluticasone Propionate Nasal Spray USP, 50 mcg per spray (OTC)
18 avr. 2019 16h05 HE
|
Akorn, Inc.
LAKE FOREST, Ill., April 18, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that it received a new Abbreviated New Drug...